Prendecki Maria, Tanna Anisha, Salama Alan D, Tam Frederick W K, Cairns Tom, Taube David, Cook H Terence, Ashby Damien, Duncan Neil D, Pusey Charles D
Imperial College Renal and Transplant Centre, Hammersmith Hospital, London, UK.
UCL Centre for Nephrology, Royal Free Hospital, London, UK.
Clin Kidney J. 2017 Apr;10(2):233-239. doi: 10.1093/ckj/sfw116. Epub 2016 Dec 24.
There are no prospective randomized controlled trials describing the outcome of acute interstitial nephritis (AIN) treated with steroids, and retrospective studies are limited. We identified adult patients with a diagnosis of AIN without glomerular pathology over a 14-year period. Treated patients all received oral prednisolone and three also recieved IV methylprednisolone. Data were collected retrospectively on estimated glomerular filtration rate (eGFR), change in eGFR from time of biopsy, dependence on renal replacement therapy (RRT) and mortality, and outcomes were analysed according to the treatment prescribed. A total of 187 eligible patients with AIN were identified and 158 were treated with steroids. There was no difference in median eGFR or dependence on RRT at the time of biopsy. Steroid-treated patients had significantly higher eGFR at all time points post-biopsy up to 24 months, when median eGFR was 43 mL/min in the steroid-treated group and 24 mL/min in the untreated group (P = 0.01). Fewer patients in the steroid-treated group were dialysis dependent by 6 months (3.2% versus 20.6%, P = 0.0022) and 24 months (5.1% versus 24.1%, P = 0.0019). This large retrospective study suggests a benefit of steroids in treatment of AIN with greater improvement in eGFR and fewer patients progressing to end-stage renal disease.
目前尚无前瞻性随机对照试验描述使用类固醇治疗急性间质性肾炎(AIN)的结果,回顾性研究也很有限。我们确定了在14年期间被诊断为AIN且无肾小球病变的成年患者。接受治疗的患者均接受了口服泼尼松龙治疗,其中3例还接受了静脉注射甲泼尼龙治疗。回顾性收集了估计肾小球滤过率(eGFR)、自活检时起eGFR的变化、对肾脏替代治疗(RRT)的依赖情况和死亡率的数据,并根据所规定的治疗方法分析结果。总共确定了187例符合条件的AIN患者,其中158例接受了类固醇治疗。活检时,两组患者的eGFR中位数或对RRT的依赖情况并无差异。在活检后的所有时间点直至24个月,接受类固醇治疗的患者的eGFR均显著更高,此时类固醇治疗组的eGFR中位数为43 mL/分钟,未治疗组为24 mL/分钟(P = 0.01)。在6个月时(3.2% 对20.6%,P = 0.0022)和24个月时(5.1% 对24.1%,P = 0.0019),接受类固醇治疗组中依赖透析的患者较少。这项大型回顾性研究表明,类固醇治疗AIN有益,可使eGFR有更大改善,且进展至终末期肾病的患者较少。